Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News argenx SE ARGX

argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-111, ARGX-109, ARGX-115, ARGX-112, and others. The company operates in the Netherlands, Germany, Denmark, Belgium, Switzerland, the United States, and Luxembourg. It derives the majority of its revenues from Switzerland.


Recent & Breaking News (NDAQ:ARGX)

argenx reports first quarter 2020 financial results and provides business update

GlobeNewswire May 14, 2020

argenx reports full year 2019 financial results and provides fourth quarter business update

GlobeNewswire February 27, 2020

argenx announces closing of global offering

GlobeNewswire November 12, 2019

argenx announces full exercise of underwriters' option to purchase additional ADSs

GlobeNewswire November 8, 2019

argenx reports third quarter 2019 financial results and provides business update

GlobeNewswire October 24, 2019

argenx to Present at Morgan Stanley 17th Annual Global Healthcare Conference

GlobeNewswire September 3, 2019

argenx to Present at 2019 Wedbush PacGrow Healthcare Conference

GlobeNewswire August 6, 2019

argenx reports half year 2019 financial results and second quarter business update

GlobeNewswire August 1, 2019

argenx to report half year 2019 financial results and second quarter business update on August 1, 2019

GlobeNewswire July 25, 2019

argenx announces pipeline expansion and "argenx 2021" vision to build integrated immunology company at 2019 R&D Day

GlobeNewswire May 22, 2019

argenx and Halozyme enter global collaboration and license agreement for ENHANZE® technology

GlobeNewswire February 4, 2019

argenx announces new cusatuzumab (ARGX-110) AML data in abstracts published in connection with 60th American Society of Hematology Annual Meeting and Exposition

GlobeNewswire November 1, 2018

argenx reports third quarter 2018 financial results and provides business update

GlobeNewswire October 24, 2018

argenx awarded €2.6 million VLAIO grant to explore new applications of ABDEG technology

GlobeNewswire October 8, 2018

argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody

GlobeNewswire August 22, 2018

argenx to Present at 2018 Wedbush PacGrow Healthcare Conference

GlobeNewswire August 9, 2018

argenx receives second preclinical milestone payment under its development agreement with AbbVie

GlobeNewswire June 28, 2018

argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris

GlobeNewswire June 20, 2018

argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation

GlobeNewswire June 14, 2018

argenx selected for BEL 20 Index

GlobeNewswire June 5, 2018